The Management of Lymphoma in the Setting of Pregnancy
- 272 Downloads
The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors, of which the most influential are the trimester at diagnosis, the stage, and aggressiveness of the disease and the presence of life-threatening symptoms. Recent data suggest that deferral of therapy until after the first trimester is desirable if it is perceived that postponement of therapy will not compromise maternal outcome. For some patients, delay of therapy to the postpartum period is feasible.
KeywordsLymphoma Pregnancy Hodgkin lymphoma Therapy
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 8.• Rimawi BH, Green V, Lindsay M. Fetal implications of diagnostic radiation exposure during pregnancy: evidence-based recommendations. Clin Obstet Gynecol. 2016;59:412–8. Evidence-based recommendations for diagnostic radiographic studies during pregnancy with concise review of radiation doses associated with fetal risk as well as radiation doses from standard radiological studies CrossRefPubMedGoogle Scholar
- 12.Abdel-Hady el S, Hemida RA, Gamal A, et al. Cancer during pregnancy: perinatal outcome after in utero exposure to chemotherapy. Arch Gynecol Obstet. 2012;286:283–6.Google Scholar
- 13.•• Evens AM, Advani R, Press OW, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol. 2013;31:4132–9. Largest multi-institutional study of 90 patients with lymphoma diagnosed during pregnancy. There was no significant difference in maternal or fetal complications between the women that received antenatal therapy as compared to those who had treatment deferred to the postpartum period. No patient received treatment during the first trimester of pregnancy CrossRefPubMedGoogle Scholar
- 14.•• Pinnix CC, Osborne EM, Chihara D, et al. Maternal and fetal outcomes after therapy for Hodgkin or non-Hodgkin lymphoma diagnosed during pregnancy. JAMA Oncol. 2016;2:1065–9. Single institutional study of 39 patients diagnosed with lymphoma while pregnant at MDACC. There was no statistically significant difference in maternal outcome according to receipt of antenatal therapy. Four miscarriages occurred, all among patients treated during pregnancy, with 2 of the 4 occurring in patients that receive first trimester therapy CrossRefPubMedGoogle Scholar
- 25.•• Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13:256–64. Multicenter case-control study of 129 children born to mothers diagnosed with cancer during pregnancy matched to children of mothers without cancer. Gestational age at the time of delivery (i.e., prematurity) was associated with inferior cognitive outcome in both groups. There was no adverse effect of antenatal therapy detected in this study CrossRefPubMedGoogle Scholar
- 26.Maternal Cancer During Pregnancy and Risks of Stillbirth and Infant Mortality. Lu D, Ludvigsson JF, Smedby KE, Fall K, Valdimarsdóttir U, Cnattingius S, Fang F. J Clin Oncol. 2017 Mar 6:JCO2016699439. doi: 10.1200/JCO.2016.69.9439. [Epub ahead of print] PMID: 28384079